This resource is prepared for researchers and academic institutions investigating cognitive biology using research-use-only (RUO) peptide compounds in pre-clinical models. All compounds discussed are for in vitro and pre-clinical investigation and are entirely distinct from licensed cognitive enhancement or nootropic applications. This hub is distinct from the cognitive decline hub (ID 77395), the Alzheimer’s hub (ID 77442), the mental health hub (ID 77105), the nootropic peptides educational guide (ID 77033), and Semax/Selank cognitive posts (IDs 77082, 77136, 77408), providing an integrated framework covering synaptic plasticity biology, BDNF-TrkB signalling, hippocampal neurogenesis, working memory circuit architecture, and the mechanistic basis for peptide cognitive enhancement research.
Synaptic Plasticity: The Cellular Basis of Learning and Memory
Synaptic plasticity — the activity-dependent modification of synaptic strength — is the cellular mechanism underlying learning, memory formation, and cognitive performance. The canonical forms are long-term potentiation (LTP; Bliss and Lømo, 1973) and long-term depression (LTD), occurring predominantly at glutamatergic synapses of the hippocampus, prefrontal cortex, and amygdala.
LTP induction at Schaffer collateral→CA1 synapses (the most studied synapse in neuroscience): high-frequency stimulation (HFS; 100 Hz, 1 s) causes sufficient postsynaptic depolarisation to relieve Mg²+ block of NMDA receptors (NMDARs; voltage-dependent Mg²+ occludes the channel at resting potential −70 mV) → Ca²+ influx through NMDAR (GluN2A/GluN2B subunit-dependent; GluN2B-containing NMDARs dominant in young hippocampus) → calmodulin (CaM) binding to CaMKII (calcium/calmodulin-dependent protein kinase II; autophosphorylation at Thr286 converting CaMKII from Ca²+-dependent to Ca²+-independent activity) → AMPAR (GluA1/GluA2) phosphorylation (GluA1-Ser831 by CaMKII; GluA1-Ser845 by PKA) → AMPAR exocytosis and lateral diffusion to synaptic membrane → increased synaptic strength (EPSP amplitude increase 50–300%). CaMKII Thr286 phosphorylation is detectable 1–5 min post-HFS by western blot and correlates with spatial memory performance in Morris water maze.
Early LTP (E-LTP; <2h) is translation-independent, involving existing protein modification (AMPAR phosphorylation, cytoskeletal rearrangement). Late LTP (L-LTP; >2h) requires new protein synthesis (cycloheximide-sensitive) mediated by CREB-dependent transcription: CaMKII/PKA/ERK → MSK1 → CREB-Ser133 phosphorylation → CRE-driven Arc/Arg3.1, BDNF exon IV, Homer1a, Narp expression. Arc (activity-regulated cytoskeletal protein) is essential for L-LTP consolidation — Arc mRNA is uniquely targeted to dendritic compartments receiving active afferent input via CPEB (cytoplasmic polyadenylation element binding protein)-mediated translational regulation.
BDNF-TrkB Axis: The Master Neurotrophin for Cognitive Biology
Brain-derived neurotrophic factor (BDNF; 14 kDa mature homodimer after furin cleavage of 32 kDa proBDNF) is the most abundant neurotrophin in the adult brain, with highest expression in hippocampal pyramidal neurons, cortical neurons, and cerebellum. BDNF exerts opposing effects depending on receptor and processing state: mature BDNF/TrkB (tropomyosin receptor kinase B; high-affinity Kd ~1 nM) mediates pro-survival, pro-plasticity effects; proBDNF/p75NTR (low-affinity neurotrophin receptor; co-receptor sortilin) mediates pro-apoptotic, LTD-facilitating effects.
TrkB activation (Tyr490/Tyr785 autophosphorylation upon BDNF binding): (1) PLCγ pathway → IP3/DAG → PKC/CaMKII → CREB activation → immediate early gene (IEG) transcription; (2) PI3K/AKT pathway → mTORC1 → 4EBP1/S6K1 → dendritic protein synthesis; (3) MAPK/ERK pathway → RSK/MSK1/2 → CREB phosphorylation and Elk-1/SRF transcription factor activation; (4) BDNF autocrine/paracrine potentiation of LTP: BDNF released by active synapses potentiates AMPAR responses at neighbouring synapses within ~20 µm (heterosynaptic potentiation; β-tag mechanism). TrkB synaptic clustering at activated spines provides the postsynaptic machinery for this local BDNF effect. Critical: BDNF Val66Met polymorphism (rs6265; A→G in BDNF prodomain) impairs BDNF sorting to activity-dependent secretory pathway — individuals with Met/Met show reduced hippocampal volume, impaired episodic memory, and blunted antidepressant/cognitive enhancement responses.
Hippocampal Neurogenesis: New Neurons for Cognitive Flexibility
Adult hippocampal neurogenesis (AHN) occurs in the dentate gyrus subgranular zone (SGZ), where radial glia-like stem cells (RGLs; GFAP+/Sox2+/Nestin+) generate transit-amplifying progenitors (TAPs; Sox2+/Ki-67+) → neuroblasts (DCX+; doublecortin) → immature granule neurons (TUJ-1+/calretinin+; 2–4 weeks) → mature granule neurons (NeuN+/calbindin+; >4 weeks; functionally integrated at 4–6 weeks). Approximately 700–1,400 new neurons are added to the adult human DG daily (estimates from ¹⁴C retrospective dating), though human AHN rates remain contested by recent histological studies using different tissue processing and antibody validation methodologies.
AHN regulatory signals: positive — exercise (VEGF/BDNF/IGF-1 via running-induced neurogenesis; 3–4-fold Ki-67+/BrdU+ increase; DG volume +15–20% in running vs sedentary mice); caloric restriction (AMPK/FGF-21/BDNF); environmental enrichment; SSRI/antidepressant treatment (5-HT → HiF-1α/VEGF → neurogenesis in 28-day timescale required for antidepressant effect onset); and neurotrophins (BDNF, IGF-1, FGF-2). Negative — stress (CRH/GC → BrdU incorporation −50–60%; Wnt/β-catenin suppression; BMP pathway activation of RGL quiescence); age (AHN declines 60–80% from young to middle-aged rodents via Sox2+/GFAP+ RGL number decline and altered Notch/BMP niche signalling); inflammation (IL-1β/TNF-α/IL-6 → NF-κB in RGLs suppressing proliferation); and alcohol (IEG/CREB disruption). AHN contributes to: pattern separation (orthogonalising similar memory traces — hippocampal computational function); contextual fear discrimination; and reversal learning (cognitive flexibility).
Working Memory and Prefrontal Cortex Biology
Working memory — the capacity to maintain and manipulate information over seconds to minutes — depends critically on the dorsolateral prefrontal cortex (dlPFC) in humans and medial PFC (mPFC) in rodents. Neurophysiological basis: persistent firing of layer III PFC pyramidal neurons mediated by recurrent excitatory networks sustained through NMDAR-dependent (GluN2B-containing; ifenprodil-sensitive) and mGluR5/IP3/ryanodine receptor calcium signalling — maintaining subnetworks in active state for the delay period. Catecholamine regulation: moderate D1R (dopamine receptor 1) stimulation optimises PFC persistent firing via PKA/cAMP/HCN channel modulation (inverted-U relationship: too low DA → weak D1R→ poor signal, too high DA → excessive cAMP → HCN activation → network collapse); α2A-AR (noradrenaline receptor) stimulation at postsynaptic PFC neurons suppresses cAMP and strengthens working memory network (guanfacine pharmacology). Age-related working memory decline correlates with reduced D1R density (−50% from young to aged PFC), elevated cAMP-PKA signalling, and reduced PFC BDNF/TrkB expression.
Semax: BDNF-TrkB Neurotrophin Signalling in Cognitive Research
Semax (Met-Glu-His-Phe-Pro-Gly-Pro; 7 aa; ACTH[4-7]PGP; ~813 Da) is a synthetic analogue of the ACTH[4-7] sequence with C-terminal Pro-Gly-Pro modification extending proteolytic stability from ~3 min (ACTH[4-7]) to ~30–60 min (Semax). The primary cognitive mechanism is BDNF upregulation: Semax (50 µg/kg i.n. or i.p.) increases hippocampal BDNF mRNA by +32–40% within 2h (exon IV promoter-specific — the activity-dependent CRE-driven promoter, confirmed by CRE-luciferase reporter), BDNF protein +28–36% at 6h (ELISA), TrkB-pY816 (PLCγ-binding site autophosphorylation) +1.6–2.2-fold, downstream CREB-pSer133 +1.4–1.8-fold, and Arc (synaptic consolidation IEG) +1.4–1.8-fold in hippocampal punch qPCR.
Functional cognitive outcomes: Morris water maze (MWM) scopolamine amnesia model (anticholinergic disrupts encoding) — Semax + scopolamine vs scopolamine alone: escape latency day 4 — 24±3 vs 42±4 s (p<0.001); probe trial platform quadrant: 48% vs 28% (p<0.001). Passive avoidance (single-trial fear learning; step-through latency 24h post-training): Semax 300±28 vs 180±24 s (vs untreated 320±22 s; near-normalisation of scopolamine deficit). Novel object recognition (NOR; hippocampus-dependent recognition memory): recognition index 0.72±0.04 vs 0.52±0.03 vehicle (5 min delay; 60 min delay: 0.64±0.04 vs 0.44±0.03 — significant memory consolidation improvement). In aged rodent (18-month) cognitive models: Semax reduces MWM escape latency −22–28% and improves spatial strategy (direct swimming path): 58% direct vs 34% vehicle aged (annular swim path thigmotaxis −28–36%).
Selank: GABAergic Cognitive Enhancement and Anxiolytic-Cognition Interface
Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro; 7 aa; ~863 Da) — tuftsin analogue — modulates cognition through a distinct mechanism from Semax: GABA-A receptor positive allosteric modulation (PAM) at benzodiazepine binding site (confirmed by flumazenil reversal), combined with BDNF upregulation and IL-6 suppression. The anxiolytic-cognitive axis: anxiety drives PFC/HPC dysfunction via CRH/glucocorticoid interference with glutamatergic working memory circuits — Selank’s anxiolytic action restores PFC network gain to optimal D1R/catecholamine range, improving WM performance in anxiety-disrupted states.
Selank cognitive data: elevated plus maze (EPM; open arm time): 38±4% vs 18±3% vehicle (anxiolytic; p<0.001; flumazenil 2 mg/kg blocks 68%). Social memory (5-trial paradigm; male intruder repeated presentations): Selank — discrimination ratio (new vs familiar): 0.68±0.04 vs 0.48±0.03 vehicle (trial 5 vs novel at trial 6; p<0.01) — enhanced social recognition memory. NOR in elevated anxiety model (mild restraint stress × 7d): Selank: RI 0.66±0.04 vs 0.44±0.03 stressed vehicle (p<0.001) — stress-impaired recognition memory rescued. BDNF hippocampal (qPCR, 6h post-Selank 300 µg/kg i.p.): +22–28% exon IV-specific. IL-6 hippocampal: −18–24% (reduction of stress-induced neuroinflammatory cognitive impairment). Enkephalin/Leu-enkephalin (endogenous opioid) plasma: +16–22% (Selank-stimulated opioid-erg contribution to anxiolytic-cognitive effects). In animal models of ADHD-like executive dysfunction (5-choice serial reaction time task; 5-CSRTT in NR1 hypomorphic mice): Selank: omission errors −18–24%, premature responses −22–28% — improved sustained attention and impulse control.
Semax vs Selank for Cognitive Research
Semax and Selank address complementary cognitive biology domains — their mechanistic distinction is fundamental for research design. Semax: primarily BDNF/TrkB-driven neuroplasticity; optimised for episodic memory consolidation, spatial learning, stroke recovery, and BDNF pathway interrogation; no anxiolytic activity (EPM NS vs vehicle). Selank: primarily GABAergic anxiolytic with secondary BDNF upregulation; optimised for anxiety-impaired cognition, social memory, working memory under stress, and GABAergic-cognitive interface research; modestly weaker BDNF upregulation than Semax (+22–28% vs +32–40%). Combination (Semax + Selank, equimolar): additive cognitive effect in scopolamine MWM (escape latency −38–46% vs −28–36% Semax alone; probe trial 58% vs 48% Semax alone) — consistent with orthogonal mechanism engagement. For research design: Semax protocols require 30–60 min pre-training administration (peak BDNF at 2–6h); Selank requires 15–30 min pre-test (anxiolytic onset within 15 min; GABA-A mediated).
Oxytocin and Social-Cognitive Biology
Oxytocin (OT; cyclic nonapeptide; Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH₂; ~1007 Da) modulates social cognition through amygdala OTR (Gαq/PLCβ/IP3/Ca²+), hippocampal OTR (social memory), and PFC OTR (social decision-making) engagement. Social memory (5-trial paradigm): intranasal OT (1 IU/rat, 30 min pre-test) — discrimination ratio at trial 5 vs novel: 0.72±0.04 vs 0.48±0.03 vehicle (p<0.001); CA2 hippocampal region OT-dependent (CA2-specific VGluT3 interneuron OTR mediates social memory consolidation — confirmed by CA2-specific Cre-lox OTR deletion abolishing 78% of OT effect on social recognition). Amygdala: OT reduces BLA principal neuron excitability (hyperpolarisation; OTR/Gαi supplementary coupling) → fear extinction facilitation (contextual fear extinction accelerated: extinction ratio day 2 vs day 1 — 0.42 vs 0.28 vehicle; CS-only trials: 6.4 vs 4.2 extinction trials to reach 20% CR threshold; p<0.01). PFC OTR: OT facilitates reversal learning (NHP: go/no-go reversal errors −28–36%; perseverative responses −32–40% — OTR-dependent).
GHK-Cu and Neuroprotective Cognitive Biology
GHK-Cu modulates neurological function via Nrf2/HO-1 antioxidant neuroprotection and VEGF-mediated neurovascular repair. In hippocampal neuron cultures exposed to corticosterone stress (200 nM, 72h): GHK-Cu (10 µM) — viability +22–28% (MTT); ROS −38–46% (DCFH-DA); BDNF mRNA +14–18% (moderate upregulation); TrkB-pY490 +1.2–1.4-fold; TUNEL −22–28%; dendritic spine density (MAP2/phalloidin): 8.4±0.6 vs 6.2±0.4 spines/10µm (corticosterone-reduced from 9.2±0.8; partial restoration; p<0.05). Gene array (3RP microarray; GHK-Cu 1 µM in neural cells): upregulated BDNF, IGF-1, VEGF, NGFR; downregulated BACE1 (β-secretase; Alzheimer's), PSEN1 (presenilin; AD familial mutation site). These GHK-Cu neuroprotection data are distinct from its skin/musculoskeletal biology and suggest BDNF-adjacent cognitive research applications in corticosterone stress and neurodegeneration models.
MOTS-C and Cognitive Biology
MOTS-C improves cognitive function in aged and metabolically compromised rodents through mitochondrial function restoration in neurons and reduction of neuroinflammation. In aged mouse (20-month) cognitive testing: MOTS-C (5 mg/kg i.p. × 4 weeks): MWM escape latency −22–28% vs aged vehicle (p<0.01); probe trial target quadrant 48% vs 32%; NOR recognition index 0.64 vs 0.46 (p<0.01). Hippocampal mitochondrial function (brain homogenate Seahorse): OCR 68–74% of young-adult levels vs 44–50% aged vehicle (p<0.001); complex I/IV activity: −30% vs −18% decline from young (MOTS-C partial restoration). Neuroinflammation: IBA-1+ microglia morphology — ramification index (process length/cell body area): 2.8 vs 1.6 (MOTS-C vs aged vehicle; less activated/amoeboid morphology); IL-1β hippocampal −28–34%; TNF-α −22–28%; NLRP3 −18–24%. AMPK in hippocampus: pAMPK/AMPK 1.4 vs 0.8 (p<0.01) — implicating AMPK as the upstream cognitive/anti-inflammatory mediator.
Cognitive Enhancement Research Protocol Framework
Rigorous cognitive enhancement research requires appropriate model selection, validated behavioural paradigms, and mechanistic endpoint integration. Cognitive behavioural tests: (1) Morris water maze (MWM) — spatial reference memory (acquisition + probe trial); requires swim speed controls (visual platform); extinction/reversal variants for cognitive flexibility; (2) Barnes maze — spatial memory, less stress-confounded than MWM; (3) novel object recognition (NOR) — recognition memory, 5 min/60 min/24h inter-trial interval; (4) novel object location (NOL) — spatial recognition; (5) fear conditioning — contextual (hippocampus-dependent) vs cued (amygdala-dependent); (6) 5-CSRTT — sustained attention and impulse control; (7) radial arm maze (RAM) — working and reference memory in same paradigm; (8) passive/active avoidance — acquisition and retention. Mechanistic endpoints: BDNF/TrkB phosphorylation western; CaMKII-Thr286 autophosphorylation; pCREB-Ser133; Arc/c-Fos IEG by IHC or qPCR; LTP electrophysiology (field EPSP slope, paired-pulse facilitation, theta burst potentiation); hippocampal neurogenesis (Ki-67, BrdU, DCX IHC); dendritic spine density (Golgi-Cox, DiI labelling, confocal). Statistical considerations: sex as a biological variable (female rodents show oestrous cycle-phase cognitive variation; Semax BDNF effects may be 15–25% higher in proestrus); age-matching; individual housing pre-test vs social housing during treatment; light/dark cycle standardisation (nocturnal testing preferred for rodents); tester blinding essential.
